公开(公告)号：US20100196931A1

公开(公告)日：2010-08-05

申请号：US12621796

申请日：2009-11-19

申请人： Ulrich Brennscheidt ,  Otmar Herrgott ,  Astrid Heller ,  Verena Lutz ,  Joachim Moecks ,  Carol Ward

发明人： Ulrich Brennscheidt ,  Otmar Herrgott ,  Astrid Heller ,  Verena Lutz ,  Joachim Moecks ,  Carol Ward

IPC分类号： G01N33/53 ,  C07K16/18 ,  C12Q1/02

CPC分类号： G01N33/573 ,  G01N33/574 ,  G01N33/57423 ,  G01N2333/9121 ,  G01N2500/00 ,  G01N2800/52

摘要： The present invention relates to a method of determining whether a biological sample comprising human lung cancer cells is sensitive to a combination of an epidermal growth factor receptor inhibitor and a chemotherapeutic agent by determining the overexpression of a phosphorylated AKT protein and/or a phosphorylated MAPK protein in the biological sample. The invention is also related to methods for deriving a candidate agent or for selecting a composition for inhibiting the progression of lung cancer in a patient wherein a phosphorylated AKT protein and/or a phosphorylated MAPK protein is used.

摘要翻译： 本发明涉及通过确定磷酸化AKT蛋白和/或磷酸化MAPK蛋白的过表达来确定包含人肺癌细胞的生物样品是否对表皮生长因子受体抑制剂和化学治疗剂的组合敏感的方​​法 在生物样品中。 本发明还涉及用于衍生候选试剂或用于选择用于抑制其中使用磷酸化AKT蛋白和/或磷酸化MAPK蛋白的患者中肺癌进展的组合物的方法。

公开(公告)号：US20070054330A1

公开(公告)日：2007-03-08

申请号：US11431241

申请日：2006-05-10

申请人： Ulrich Brennscheidt ,  Otmar Herrgott ,  Astrid Heller ,  Verena Lutz ,  Joachim Moecks ,  Carol Ward

发明人： Ulrich Brennscheidt ,  Otmar Herrgott ,  Astrid Heller ,  Verena Lutz ,  Joachim Moecks ,  Carol Ward

IPC分类号： G01N33/574 ,  A61K31/517

CPC分类号： G01N33/573 ,  G01N33/574 ,  G01N33/57423 ,  G01N2333/9121 ,  G01N2500/00 ,  G01N2800/52

摘要： The present invention relates to a method of determining whether a biological sample comprising human lung cancer cells is sensitive to a combination of an epidermal growth factor receptor inhibitor and a chemotherapeutic agent by determining the overexpression of a phosphorylated AKT protein and/or a phosphorylated MAPK protein in the biological sample. The invention is also related to methods for deriving a candidate agent or for selecting a composition for inhibiting the progression of lung cancer in a patient wherein a phosphorylated AKT protein and/or a phosphorylated MAPK protein is used.

摘要翻译： 本发明涉及通过确定磷酸化AKT蛋白和/或磷酸化MAPK蛋白的过表达来确定包含人肺癌细胞的生物样品是否对表皮生长因子受体抑制剂和化学治疗剂的组合敏感的方​​法 在生物样品中。 本发明还涉及用于衍生候选试剂或用于选择用于抑制其中使用磷酸化AKT蛋白和/或磷酸化MAPK蛋白的患者中肺癌进展的组合物的方法。

公开(公告)号：US07655414B2

公开(公告)日：2010-02-02

申请号：US11431241

申请日：2006-05-10

申请人： Ulrich Brennscheidt ,  Otmar Herrgott, legal representative ,  Astrid Heller ,  Verena Lutz ,  Joachim Moecks ,  Carol Ward

发明人： Ulrich Brennscheidt ,  Astrid Heller ,  Verena Lutz ,  Joachim Moecks ,  Carol Ward

IPC分类号： G01N33/53

CPC分类号： G01N33/573 ,  G01N33/574 ,  G01N33/57423 ,  G01N2333/9121 ,  G01N2500/00 ,  G01N2800/52

摘要： The present invention relates to a method of determining whether a biological sample comprising human lung cancer cells is sensitive to a combination of an epidermal growth factor receptor inhibitor and a chemotherapeutic agent by determining the overexpression of a phosphorylated AKT protein and/or a phosphorylated MAPK protein in the biological sample. The invention is also related to methods for deriving a candidate agent or for selecting a composition for inhibiting the progression of lung cancer in a patient wherein a phosphorylated AKT protein and/or a phosphorylated MAPK protein is used.

摘要翻译： 本发明涉及通过确定磷酸化AKT蛋白和/或磷酸化MAPK蛋白的过表达来确定包含人肺癌细胞的生物样品是否对表皮生长因子受体抑制剂和化学治疗剂的组合敏感的方​​法 在生物样品中。 本发明还涉及用于衍生候选试剂或用于选择用于抑制其中使用磷酸化AKT蛋白和/或磷酸化MAPK蛋白的患者中肺癌进展的组合物的方法。